Stocks Soar Back Into Green On Yet Another Vaccine Headline

Tyler Durden's Photo
by Tyler Durden
Wednesday, Jul 01, 2020 - 09:05 AM

Another day, another "positive" vaccine headline (this time from Pfizer) and the algos can't buy stocks fast enough.

Statnews (yes, them again) report that:

"An experimental Covid-19 vaccine being developed by the drug giant Pfizer and the biotech firm BioNTech spurred immune responses in healthy patients, but also caused fever and other side effects, especially at higher doses"

"The first clinical data on the vaccine were disclosed Wednesday in a paper released on MedRXiv, a preprint server, meaning it has not yet been peer-reviewed or published in a journal. "

In the press release Pfizer said

In all 24 subjects who received 2 vaccinations at 10 µg and 30 µg dose levels of BNT162b1, elevation of RBD-binding IgG concentrations was observed after the second injection with respective GMCs of 4,813 and 27,872 units/ml at day 28, seven days after immunization. These concentrations are 8- and 46.3-times the GMC of 602 units/ml in a panel of 38 sera from subjects who had contracted SARS-CoV-2.

So no peer-review? 24 of 24? Antibodies measurable after 28 days? Sounds very "remdesivir"...

This headline sent all US equity market soaring... "virus solved"?

Pfizer is up 7%...

How long before the "medical results via press release" details are actually read by a human and considered rationally?

Do you want to be Number 25 to take this "vaccine"?